

APR 20 2005

PATENT APPLICATIONVia Facsimile - (703) 872-9306  
MAIL STOP AMENDMENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter R. Baum and William C. Fanslow, III

Serial No.: 10/622,237

Group Art Unit No.: 1644

Filed: July 17, 2003

Examiner: M. Haddad

For: ANTIBODIES THAT BIND LDCAM (AS AMENDED)

Docket No.: 2873-USA

INFORMATION DISCLOSURE STATEMENTCommissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/778,187 filed February 6, 2001. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complies with 37 CFR 1.98(a)-(c).

The above-cited list is submitted under § 1.97(c) and accompanied by the fee of \$180 as set forth in § 1.17(p). The Commissioner is authorized to charge the \$180 fee and any other fees which may be required to Deposit Account No. 09-0089. A duplicate copy of this sheet is enclosed.

Applicants request consideration of this information and passage of the application to issue.

Respectfully submitted,

  
 James E. Klaniecki  
 Attorney/Agent for Applicants  
 Registration No.: 38,207  
 Phone: (206) 265-7145

 Immunex Corporation  
 Law Department  
 1201 Amgen Court West  
 Seattle, WA 98119-3105  
 (206) 265-7000
CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below.

 Signed:   
 Nanci M. Kerton

Date: April 20, 2005

Via Facsimile - (703) 872-9306  
MAIL STOP AMENDMENT

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Peter R. Baum and William C. Fanslow, III

Serial No.: 10/622,237

Group Art Unit No.: 1644

Filed: July 17, 2003

Examiner: M. Haddad

For: ANTIBODIES THAT BIND LDCAM (AS AMENDED)

Docket No.: 2873-USA

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

In accordance with 37 CFR 1.98(d), copies of the patents, publications, pending U.S. applications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/778,187 filed February 6, 2001. The present application is a continuation of this prior application which is relied upon for an earlier filing date under 35 USC 120 and the information disclosure statement submitted in the earlier application complies with 37 CFR 1.98(a)-(c).

The above-cited list is submitted under § 1.97(c) and accompanied by the fee of \$180 as set forth in § 1.17(p). The Commissioner is authorized to charge the \$180 fee and any other fees which may be required to Deposit Account No. 09-0089. A duplicate copy of this sheet is enclosed.

Applicants request consideration of this information and passage of the application to issue.

Respectfully submitted,

  
 James E. Klaniecki  
 Attorney/Agent for Applicants  
 Registration No.: 38,207  
 Phone: (206) 265-7145

Immunex Corporation  
Law Department  
1201 Amgen Court West  
Seattle, WA 98119-3105  
(206) 265-7000

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below.

Signed:   
Nanci M. Kertson

Date: April 20, 2005

VIA Facsimile - (703) 872-9306  
Mail Stop Amendment

Sheet 1 of 2  
SERIAL NO.

<b>Form PTO-1449</b>		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NO. 2873-USA	10/622,237
<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		APPLICANT		Peter R. Baum and William C. Fanslow III	
		FILING DATE		GROUP	
		July 17, 2003		1644	

#### U.S. PATENT DOCUMENTS

EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A1		6,512,095	01.28.03	Baum			
A2		US-2002/0198147	12.2002	Baker et al.			
A3		6,642,360	11.2003	Filvaroff et al.			

#### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
B1		WO99/28462	06/10/99	PCT			
B2		WO99/57132	11/11/99	PCT			
B3		WO00/29435	05/25/00	PCT			
B4		WO00/32776	06/08/00	PCT			
B5		WO01/00237A1	01/04/01	PCT			
B6		WO01/54477A2	08/02/01	PCT			
B7		WO02/26930A2	04/04/02	PCT			

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Attwood, T. "The bable of bioinformatics," <i>Science</i> , 290:47-49, 2000.
C2	Bost, K.L. and Pascual, D.W., "Antibodies against a peptide sequence within the HIV envelope protein crossreacts with human interleukin-2," <i>Immunol. Invest.</i> , 17(6-7):577-586, 1988.
C3	Gomyo, H. et al., "A 2-Mb sequence-ready contig map and a novel immunoglobulin superfamily gene <i>IGSF4</i> in the LOH region of chromosome 11q23.2," <i>Genomics</i> , 62:139-146, 1999.
C4	Greene, J.L. et al., "Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cells costimulatory interactions," <i>J. Biol. Chem.</i> , 271(6):26762-26771, 1996.
C5	Linsley, P.S. et al., "Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4)," <i>J. Biol. Chem.</i> , 270(25):15417-15424, 1995.
C6	Metzler et al., "Solution structure of human CLTA-4 and delineation of a CD80/CD86 binding site conserved in CD28," <i>Nature Structural Biol.</i> , 4:527-531, 1997.
C7	Skolnick et al. "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <i>Trends in Biotech.</i> , 18(1):34-39, 2000.
C8	Strausberg, R., Genebank, Accession No. AA493561, August 28, 1997.

#### EXAMINER

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPIE

VIA Facsimile - (703) 872-9306  
Mail Stop Amendment

Sheet 2 of 2

<b>Form PTO-1449</b>		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY DOCKET NO. 2873-USA	SERIAL NO. 10/622,237
<b>INFORMATION DISCLOSURE CITATION</b> <i>(Supplemental Sheet)</i>		APPLICANT Peter R. Baum and William C. Fanslow III		
		FILING DATE July 17, 2003	GROUP 1644	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>				
	C9	The RIKEN Genome Exploration Research Group Phase II Team and the FANTOM Consortium; "Functional annotation of a full-length mouse cDNA collection," <i>Nature</i> 409:685-690, 2001		
	C10	Urase K., et al., Expression of TRA175 mRNA, a new member of the immunoglobulin superfamily, in developing mouse brain," <i>NeuroReport</i> 12(15):3217-3221, Oct. 2001		
	C11	Wakayama T., et al., "Cloning and Characterization of a Novel Mouse Immunoglobulin Superfamily Gene Expressed in Early Spermatogenic Cells," <i>Molecular Reproduction and Development</i> 60:158-164, 2001		
EXAMINER		DATE CONSIDERED		
<small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>				